Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
96 hedge funds and large institutions have $555M invested in Stemline Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 37 increasing their positions, 29 reducing their positions, and 17 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 29
27% more capital invested
Capital invested by funds: $436M → $555M (+$119M)
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
2% less funds holding
Funds holding: 98 → 96 (-2)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
66% less call options, than puts
Call options by funds: $784K | Put options by funds: $2.28M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$22.9M |
| 2 |
HM
HealthCor Management
New York
|
+$15.5M |
| 3 |
Millennium Management
New York
|
+$9.41M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.23M |
| 5 |
CWG
C WorldWide Group
Copenhagen,
Denmark
|
+$7.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Pier Capital
Stamford,
Connecticut
|
-$8.22M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$8.18M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$7.23M |
| 4 |
Man Group
London,
United Kingdom
|
-$5.82M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
-$5.79M |
STML Hedge Fund Activity: Q2 2019 in Review
96 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2019, worth a combined $555M — up 27% from $436M a quarter earlier.
Fund positioning in STML was balanced in Q2 2019: 17 funds opened new positions, 17 closed out, 37 added to existing stakes and 29 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $22.9M. The largest seller was Pier Capital, exiting entirely with an estimated $8.22M sold.
- 96 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2019, down from 98 in Q1 2019.
- Funds reported $555M of Stemline Therapeutics, Inc. stock for Q2 2019, up 27% quarter-over-quarter.
- 17 funds opened new Stemline Therapeutics, Inc. positions in Q2 2019 and 17 closed out, a net change of 0 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q2 2019 was Eventide Asset Management, an estimated $22.9M added.
- The largest Stemline Therapeutics, Inc. seller in Q2 2019 was Pier Capital, an estimated $8.22M sold.
Based on aggregated 13F filings for Q2 2019.